Hospital-Acquired Pneumonia Treatment Guidelines

Inadequate Coverage of Ceftriaxone and Metronidazole

The American Thoracic Society and the Infectious Diseases Society of America recommend that empiric HAP treatment must include coverage for Pseudomonas aeruginosa and other gram-negative bacilli, which ceftriaxone lacks 1, 2
Ceftriaxone plus metronidazole is not an appropriate empiric regimen for hospital-acquired pneumonia (HAP) because it lacks adequate coverage for Pseudomonas aeruginosa and other high-risk gram-negative pathogens that commonly cause HAP 1, 2, 3
Metronidazole provides anaerobic coverage that is not routinely needed for HAP unless there is suspected aspiration with necrotizing pneumonia or lung abscess 1

For low-risk HAP, the European Respiratory Society recommends using ceftriaxone as monotherapy only if the patient has low mortality risk (≤15%) and no risk factors for MDR pathogens 2, 3, 4
Acceptable alternatives for low-risk HAP include ertapenem, cefotaxime, moxifloxacin, or levofloxacin 2, 3
For high-risk HAP, the Infectious Diseases Society of America recommends using an antipseudomonal beta-lactam (piperacillin-tazobactam, cefepime, meropenem, or imipenem) 1, 2, 3

Prior intravenous antibiotic use within 90 days is a critical risk factor that mandates broader coverage 1, 5, 3
Hospitalization >5 days is a critical risk factor that mandates broader coverage 5, 3
Septic shock or need for mechanical ventilation is a critical risk factor that mandates broader coverage 1, 5, 2

The American Thoracic Society recommends not using aminoglycosides as the sole antipseudomonal agent 1, 4
The Infectious Diseases Society of America recommends not assuming ceftriaxone provides adequate coverage for HAP simply because it works for community-acquired pneumonia 1, 2, 3
The European Respiratory Society recommends always obtaining lower respiratory tract cultures before initiating antibiotics to guide de-escalation at 48-72 hours 3, 4